Though they have very different causes, type 2 and type 1 diabetes can have extremely similar symptoms because they are both defined by high blood sugar levels (hyperglycemia). Both conditions ...

Pliant Therapeutics is also conducting a Phase 1 study for another molecule, PLN-101095, aimed at solid tumors, and has obtained regulatory clearance for a Phase 1 study of PLN-101325, an antibody ...

Type 1 diabetes is an autoimmune disease in which the body mistakenly attacks healthy insulin-producing cells in the pancreas, explains Carmella Evans-Molina, M.D., Ph.D., director of Indiana ...

(KRON) — Another Bay Area biotech company has just cut dozens of jobs. In a state filing with the Employment Development Department, Pliant Therapeutics revealed it had laid off 69 people at its ...

Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the biotech disclosed after market close on 1 May. The move comes just ...

Pliant Therapeutics, a South San Francisco biotech company developing treatments for fibrosis, is slashing its staff after halting a crucial study over safety concerns. This layoff round arrives ...

Pliant Therapeutics said it would reduce its current workforce by about 45%, part of a strategic realignment to position the company for execution of late stage clinical trials. The company said ...

Pliant Therapeutics, Inc. has announced a significant restructuring aimed at reducing costs and extending its cash runway in preparation for late-stage clinical trials.

Pliant is conducting a Phase 1 study for PLN-101095, a small molecule, dual-selective inhibitor of α v ß 8 and α v ß 1 integrins, that is being developed for the treatment of solid tumors.

Death rates from diabetes peaked in 2021, according to CDC figures, at 31.1 deaths per 100,000 people for that year. Diabetes was the eighth leading cause of death in 2021.

European fintech Pliant has reportedly acquired the Austrian Insurtech hi.health. The acquisition enables Pliant to apply its payment expertise to the insurance sector while “gaining industry ...